As of Oct 18
| -0.37 / -1.02%|
The 21 analysts offering 12-month price forecasts for Pfizer have a median target of 37.00, with a high estimate of 54.00 and a low estimate of 31.00. The median estimate represents a +3.27% increase from the last price of 35.83.
The current consensus among 23 polled investment analysts is to Buy stock in Pfizer. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.